For younger patients, just like older patients with CLL, my preference for frontline treatment is based on genomic characteristics, fitness, and patient preference. I also prefer clinical trials over standard therapy, when available. For those young fit patients with IGHV mutated disease, the optio...

As above endorsement by @Nicole Lamanna, I am in very general agreement with @Jennifer A. Woyach's approach to the young CLL patient. Want to endorse the comment that for the low risk (FISH normal and no p53 mutations with IGHV mutated status) young, fit CLL patient that chemoimmunotherapy (CIT) is ...